- Home
- SVRA
SVRA
Savara Inc.
as 11-21-2024 11:39am EST
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | AUSTIN |
| Market Cap: | 739.1M | IPO Year: | N/A |
| Target Price: | $10.83 | AVG Volume (30 days): | 2.0M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.43 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.81 - $5.70 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Savara Inc. (SVRA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| RAMSAY DAVID A | SVRA | Director | Nov 18 '24 | Buy | $2.88 | 100,000 | $287,600.00 | 2,323,642 |
Latest Savara Inc. News
SVRA Breaking Stock News: Dive into SVRA Ticker-Specific Updates for Smart Investing
Argus Research
2 days ago
Daily – Vickers Top Buyers & Sellers for 11/19/2024
MT Newswires
3 days ago
Savara Insider Bought Shares Worth $287,600, According to a Recent SEC Filing
GuruFocus.com
8 days ago
Evercore Downgrades Savara on Manufacturing Concerns for Lung Disease Drug Candidate
Business Wire
8 days ago
Savara Announces Participation in Upcoming Healthcare Conferences
Business Wire
9 days ago
Savara Reports Third Quarter 2024 Financial Results and Provides Business Update
Business Wire
17 days ago
Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference
Business Wire
a month ago
Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of "The Balancing Act®" Airing on Lifetime® TV
Business Wire
a month ago
Savara Announces New Employment Inducement Grant
Compare SVRA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SVRA Savara Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.